Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment/Care Regimen; i.e. Curative, Life-extending, or PalliativeTHRIVENCT07433660
WellSpan-THRIVE Cancer QOL Study
An observational study of Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment/Care Regimen; i.e. Curative, Life-extending, or Palliative and Cancer (Solid Tumors), run by WellSpan Health at 5 sites in United States.
Trial summary
Cancer affects millions of people worldwide and can significantly impact not only survival, but also day-to-day quality of life. Treatments such as surgery, chemotherapy, and radiation can cause side effects like fatigue, pain, and neuropathy, which may affect physical function, emotional well-being, and social… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment/Care Regimen; i.e. Curative, Life-extending, or Palliative, Cancer (Solid Tumors), Cancer (With or Without Metastasis)
- How many people
- 1,000 participants
- Where
- 5 sitesUnited States
- Study dates
- Feb 2026to Dec 2031
- How long will I take part?
- 24 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Newly diagnosed with a- primary cancer within the past six months from WellSpan cancer centers.
Who may be able to join
- Age 18 years and above
- Primary cancer diagnosis (newly diagnosed within the past 6 months)
- Able to sign informed consent.
Who cannot join
- Patients with age<18 years,
- Patients with primary non-melanoma skin, neurological malignancies (Brain or brain metastases), and primary hematological malignancies.
- Patients with severe cognitive impairment, unable to sign informed consent or unable to complete quality of life questionnaire.
- Patients with life expectancy of <90 days, in the opinion of treating investigator.
Trial locations and contacts
5 sites in 1 country. Contact the study team or a site near you to ask about taking part.
5 sites in 1 country
United States5 sites, 5 recruiting
- Recruiting
WellSpan Medical Oncology & Hematology
Chambersburg, Pennsylvania, 17201
Tara Reed, RN, OCN, 717-217-6017, Treed5@wellspan.org
- Recruiting
WellSpan Ephrata Cancer Center
Ephrata, Pennsylvania, 17522
Karen Comerford, RN, OCN, 717- 721-4838, kcomerford@wellspan.org
- Recruiting
WellSpan Adams Cancer Center
Gettysburg, Pennsylvania, 17325
Erin Hill, RN, OCN, 717-339-2638, Ehill4@wellspan.org
- Recruiting
WellSpan Sechler Family Cancer Center
Lebanon, Pennsylvania, 17042
Lauren Adams, RN, 717-639-3924, Ladams10@wellspan.org
- Recruiting
WellSpan York Cancer Center
York, Pennsylvania, 17403
Joan K Moore, MSN, RN, OCN, CCRP, 717-741-8124, jmoore@wellspan.org
Rahul Kashyap, MBBS, MBA, FCCM, 717-851-4611, rkashyap@wellspan.org
About this study
Official title: WellSpan Study of Tracking Health and Resilience to Improve the Vitality of Individuals Experiencing Cancer [WellSpan-THRIVE]
Cancer affects millions of people worldwide and can significantly impact not only survival, but also day-to-day quality of life. Treatments such as surgery, chemotherapy, and radiation can cause side effects like fatigue, pain, and neuropathy, which may affect physical function, emotional well-being, and social relationships. While many studies have examined factors that influence quality of life; such as age, type and stage of cancer, and treatment-related symptoms; there is still a need for tools that more fully reflect patients' lived experiences.
This study aims to develop and implement a patient-centered quality of life (QOL) survey designed specifically for individuals with cancer. By directly involving patients in sharing what matters most to them, the survey seeks to provide a more complete and accurate understanding of how cancer and its treatment affect daily life. The results will help patients, families, and healthcare providers better identify needs, guide supportive care, and improve overall well-being throughout the cancer journey.
Read the detailed description
Cancer is a leading cause of morbidity and mortality worldwide. With more than 10 million deaths in 2020, it is imposing a significant burden on individuals, families, and healthcare systems. Cancer treatment often involves a combination of therapies, such as surgery, chemotherapy, and radiation therapy, which can lead to a range of physical and psychological side effects. Side effects such as fatigue, pain, and neuropathy can greatly affect a cancer patient's quality of life, impacting their ability to function, their emotional health, and their social relationships. Research into cancer-related quality of life (QOL) has become increasingly important, as it helps us understand how cancer impacts every part of a patient's life, not just survival. Involving patients in their own care is a powerful way to boost engagement and gain deeper insight into the factors that influence quality of life during the cancer journey.
Many studies have looked at what affects quality of life (QOL) in cancer patients. Factors such as age, stage of disease, type of cancer, education, income, and treatment side effects all play a role. For example, older age, advanced cancer, and certain types like lung or pancreatic cancer can lower QOL, while treatment side effects such as fatigue, pain, and neuropathy can make it harder for patients to do daily activities and enjoy life. Research has made important progress in understanding how physical, emotional, and social issues impact well-being, but challenges remain in fully capturing all the factors that influence QOL for people living with cancer.
The goal is to bridge this gap by developing and implementing a patient-centered quality of life (QOL) survey tailored specifically for cancer patients and aims to capture a more accurate and comprehensive picture of the factors that affect their quality of life.
- Conditions
- Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment/Care Regimen; i.e. Curative, Life-extending, or Palliative, Cancer (Solid Tumors), Cancer (With or Without Metastasis), Cancer - Ovarian, Cancer Abdomen, Cancer (Advanced Stage)
- Keywords
- Cancer, Quality of Life, QOL, Registry, Patient
- Medical subject headings
- Neoplasms, Ovarian Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients Diagnosed with primary cancer in past 6 months | Patients Diagnosed with primary cancer in past 6 months will be divided into Race, ethnicity and gender and will be looked for differences in quality of life based on these subsets. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Quality of Life Differences based on Race or Ethnicity or Gender
Quality of Life Differences based on Race or Ethnicity or Gender based on Quality-of-life questionnaire. We will look for changes in each question on Quality-of-life from baseline to 6-12-18-24 months.
Measured: Baseline, 6-12-18-24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Feb 2026
- Study startFeb 2026 (estimated)
- Primary completionFeb 2031 (estimated)
- Study completionDec 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment/Care Regimen; i.e. Curative, Life-extending, or PalliativeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,000 participants (estimated)
- Target duration
- 24 Months
Sponsor and investigators
- Lead sponsor
- WellSpan Health
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Rahul Kashyap, WellSpan Health
- Investigators
- Navesh Sharma, DO, PhD, FACRO, Principal investigator, WellSpan Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07433660
- Sponsor's protocol ID
- 2226965-1
- Acronym
- THRIVE
- Status last verified
- Feb 2026
- First submitted
- 19 Feb 2026
- Last updated
- 2 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: We don't have patient and institution permission to share individual participant data (IPD).
Publications
Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993 Mar;11(3):570-9. doi: 10.1200/JCO.1993.11.3.570.
PubMed 8445433Dodd MJ, Miaskowski C, Paul SM. Symptom clusters and their effect on the functional status of patients with cancer. Oncol Nurs Forum. 2001 Apr;28(3):465-70.
PubMed 11338755Yennurajalingam S, Rodrigues LF, Shamieh O, Tricou C, Filbet M, Naing K, Ramaswamy A, Perez-Cruz PE, Bautista MJS, Bunge S, Muckaden MA, Sewram V, Fakrooden S, Noguera-Tejedor A, Rao SS, Liu D, Park M, Williams JL, Lu Z, Cantu H, Hui D, Reddy SK, Bruera E. Perception of Curability Among Advanced Cancer Patients: An International Collaborative Study. Oncologist. 2018 Apr;23(4):501-506. doi: 10.1634/theoncologist.2017-0264. Epub 2017 Nov 20.
PubMed 29158371Grabner M, Molife C, Wang L, Winfree KB, Cui ZL, Cuyun Carter G, Hess LM. Data Integration to Improve Real-world Health Outcomes Research for Non-Small Cell Lung Cancer in the United States: Descriptive and Qualitative Exploration. JMIR Cancer. 2021 Apr 12;7(2):e23161. doi: 10.2196/23161.
PubMed 33843600Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
PubMed 33538338
Study at a glance
From the registry record, last updated by the sponsor on 2 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- WellSpan Study of Tracking Health and Resilience to Improve the Vitality of Individuals Experiencing Cancer [WellSpan-THRIVE]
- ClinicalTrials.gov ID
- NCT07433660
- Acronym / sponsor ID
- THRIVE / 2226965-1
- Conditions
- Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment/Care Regimen; i.e. Curative, Life-extending, or Palliative, Cancer (Solid Tumors), Cancer (With or Without Metastasis), Cancer - Ovarian, Cancer Abdomen, Cancer (Advanced Stage)
- Keywords
- Cancer, Quality of Life, QOL, Registry, Patient
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- WellSpan HealthUniversity, hospital or other
- Study start
- Feb 2026 (estimated)
- Primary completion
- Feb 2031 (estimated)
- Study completion
- Dec 2031 (estimated)
- First posted
- 25 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cancer affects millions of people worldwide and can significantly impact not only survival, but also day-to-day quality of life. Treatments such as surgery, chemotherapy, and radiation can cause side effects like fatigue, pain, and neuropathy, which may affect physical function, emotional well-being, and social relationships. While many studies have examined factors that influence quality of life; such as age, type and stage of cancer, and treatment-related symptoms; there is still a need for tools that more fully reflect patients' lived experiences.
This study aims to develop and implement a patient-centered quality of life (QOL) survey designed specifically for individuals with cancer. By directly involving patients in sharing what matters most to them, the survey seeks to provide a more complete and accurate understanding of how cancer and its treatment affect daily life. The results will help patients, families, and healthcare providers better identify needs, guide supportive care, and improve overall well-being throughout the cancer journey.
Detailed description
Cancer is a leading cause of morbidity and mortality worldwide. With more than 10 million deaths in 2020, it is imposing a significant burden on individuals, families, and healthcare systems. Cancer treatment often involves a combination of therapies, such as surgery, chemotherapy, and radiation therapy, which can lead to a range of physical and psychological side effects. Side effects such as fatigue, pain, and neuropathy can greatly affect a cancer patient's quality of life, impacting their ability to function, their emotional health, and their social relationships. Research into cancer-related quality of life (QOL) has become increasingly important, as it helps us understand how cancer impacts every part of a patient's life, not just survival. Involving patients in their own care is a powerful way to boost engagement and gain deeper insight into the factors that influence quality of life during the cancer journey.
Many studies have looked at what affects quality of life (QOL) in cancer patients. Factors such as age, stage of disease, type of cancer, education, income, and treatment side effects all play a role. For example, older age, advanced cancer, and certain types like lung or pancreatic cancer can lower QOL, while treatment side effects such as fatigue, pain, and neuropathy can make it harder for patients to do daily activities and enjoy life. Research has made important progress in understanding how physical, emotional, and social issues impact well-being, but challenges remain in fully capturing all the factors that influence QOL for people living with cancer.
The goal is to bridge this gap by developing and implementing a patient-centered quality of life (QOL) survey tailored specifically for cancer patients and aims to capture a more accurate and comprehensive picture of the factors that affect their quality of life.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 24 Months
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients Diagnosed with primary cancer in past 6 months | – | –Patients Diagnosed with primary cancer in past 6 months will be divided into Race, ethnicity and gender and will be looked for differences in quality of life based on these subsets. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Newly diagnosed with a- primary cancer within the past six months from WellSpan cancer centers.
Key inclusion criteria (3 listed)
- Age 18 years and above
- Primary cancer diagnosis (newly diagnosed within the past 6 months)
- Able to sign informed consent.
Key exclusion criteria (4 listed)
- Patients with age<18 years,
- Patients with primary non-melanoma skin, neurological malignancies (Brain or brain metastases), and primary hematological malignancies.
- Patients with severe cognitive impairment, unable to sign informed consent or unable to complete quality of life questionnaire.
- Patients with life expectancy of <90 days, in the opinion of treating investigator.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Quality of Life Differences based on Race or Ethnicity or Gender
Time frame: Baseline, 6-12-18-24 months
Quality of Life Differences based on Race or Ethnicity or Gender based on Quality-of-life questionnaire. We will look for changes in each question on Quality-of-life from baseline to 6-12-18-24 months.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Mar 2026.
- Background: PubMed 8445433Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993 Mar;11(3):570-9. doi: 10.1200/JCO.1993.11.3.570.
- Background: PubMed 11338755Dodd MJ, Miaskowski C, Paul SM. Symptom clusters and their effect on the functional status of patients with cancer. Oncol Nurs Forum. 2001 Apr;28(3):465-70.
- Background: PubMed 29158371Yennurajalingam S, Rodrigues LF, Shamieh O, Tricou C, Filbet M, Naing K, Ramaswamy A, Perez-Cruz PE, Bautista MJS, Bunge S, Muckaden MA, Sewram V, Fakrooden S, Noguera-Tejedor A, Rao SS, Liu D, Park M, Williams JL, Lu Z, Cantu H, Hui D, Reddy SK, Bruera E. Perception of Curability Among Advanced Cancer Patients: An International Collaborative Study. Oncologist. 2018 Apr;23(4):501-506. doi: 10.1634/theoncologist.2017-0264. Epub 2017 Nov 20.
- Background: PubMed 33843600Grabner M, Molife C, Wang L, Winfree KB, Cui ZL, Cuyun Carter G, Hess LM. Data Integration to Improve Real-world Health Outcomes Research for Non-Small Cell Lung Cancer in the United States: Descriptive and Qualitative Exploration. JMIR Cancer. 2021 Apr 12;7(2):e23161. doi: 10.2196/23161.
- Background: PubMed 33538338Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
- Individual participant dataSharing planned: No. We don't have patient and institution permission to share individual participant data (IPD).
Related trials for Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment/Care Regimen; i.e. Curative, Life-extending, or Palliative
RecruitingObservational study
Is the 1939 Cancer Act Fit for Purpose in the Modern Technology Era?
Cancer, Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment/Care Regimen; i.e. Curative, Life-extending, or Palliative
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Navesh Sharma, DO, PhD, FACRO principal investigator
WellSpan Health
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment/Care Regimen; i.e. Curative, Life-extending, or Palliative and Cancer (Solid Tumors), run by WellSpan Health at 5 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Joan K Moore, MSN, RN, OCN, CCRP (717-741-8124, jmoore@wellspan.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Quality of Life Differences based on Race or Ethnicity or Gender (time frame: Baseline, 6-12-18-24 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07433660, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Mar 2026.